Catherine Moukheibir Purchases Shares of MoonLake Immunotherapeutics

Catherine Moukheibir recently bought 22,195 shares of MoonLake Immunotherapeutics, trading on the NasdaqCM under the ticker MLTX. This transaction took place on June 17, 2026, and reflects a significant insider move within the company.

MoonLake Immunotherapeutics Stock Snapshot

Shares of NasdaqCM:MLTX were trading around $19.19. MoonLake Immunotherapeutics has a market cap of approximately $1.41 billion. Despite not being profitable, as indicated by its negative forward P/E ratio, the company has a beta of 1.036, suggesting moderate volatility. The stock's 52-week range spans from a low of $5.95 to a high of $62.75, with a 50-day moving average of $17.88 and a 200-day moving average of $19.01. The company maintains a strong liquidity position with a current ratio of 8.601 and a quick ratio of 7.887, though it has a debt-to-equity ratio of 39.682.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a biotechnology company focused on developing treatments for inflammatory skin and joint diseases. The company is working on Sonelokimab, a novel treatment targeting conditions like hidradenitis suppurativa and psoriatic arthritis. Founded in 2021, MoonLake is based in Zug, Switzerland, and is led by CEO Dr. Jorge Santos da Silva. With around 130 employees, the company aims to advance therapies in dermatology and rheumatology.

Bottom Line

Catherine Moukheibir's recent purchase of MoonLake Immunotherapeutics shares highlights insider confidence in the company's potential. As a clinical-stage biotech firm, MoonLake is focused on innovative treatments for inflammatory diseases. Investors often watch insider transactions like this for insights into company sentiment, though it's important to remember that such moves are not always indicative of future performance.